Trikafta Patent, Sales & Clinical Trials Insight 2028 Report Analysis & Data Highlights:
- Trikafta Patent Insight
- Trikafta Dosage & Price
- Trikafta Sales Forecast 2028: > USD 5 Billion
- Trikafta Chemistry & Pharmacokinetic Properties
- Trikafta Ongoing Clinical Trials: > 15 Clinical Studies
- Role in Cystic Fibrosis
- Trikafta Reimbursement Scenario
The successful mapping of human genome and advances in molecular technology has led to evolution of targeted therapies. The identification of cystic fibrosis transmembrane conductor regulator (CFTR) gene and its potential role in the progression of cystic fibrosis has surged the research and development of targeted drugs towards CFTR genes. Researchers have developed CFTR modulator agents which are small molecules which modulate the function of abnormal CFTR protein. To date, four CFTR modulators have been approved for the treatment of cystic fibrosis.
Trikafta is the first triple combinational therapy involving elexacaftor, tezacaftor, and ivacaftor. The drug is indicated for the management of cystic fibrosis in patients ages 12 years and older who have at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The novel drug Trikafta was designed to increase the quantity and function of the F508del-CFTR protein at the cell surface. The drug has gained approval in US and Europe. It is expected that the drug will also be approved in China and Japan during the forecast period, which will further propel the market.
The approval of drug Trikafta was supported by the positive results of two global Phase 3 studies in people ages 12 years and older with cystic fibrosis including a 24-week Phase 3 study in 403 people with one F508del mutation and one minimal function mutation (F/MF) and a 4-week Phase 3 study in 107 people with two F508del mutations (F/F). The results from the trial indicated that clinically meaningful improvements were seen in patients and the drug has demonstrated safety and tolerability in cystic fibrosis patients.
The entrance of the drug Trikafta has greatly revolutionized the overall cystic fibrosis treatment as it combines the properties of all three previously approved CFTR modulators. Owing to its high specificity towards of cystic fibrosis transmembrane conductor regulator (CFTR) gene and ability to overcome the resistance limitations of already approved drugs, the report analyzes that the coming years will witness high growth rates in the global sales of Trikafta.
Important advances in the clinical outcomes have been shown since the introduction of Trikafta. Unfortunately, the therapy is currently associated with substantial cost and as results is not available for all eligible patients. However, considerable initiatives by government and public sectors have led to the development of favorable reimbursement policies which aim to enhance their uptake in market. For instance, Vertex GPS program was developed which provide financial support services, reimbursement support, and ongoing product-related materials for eligible enrolled patients who have been prescribed Trikafta.
The report offers compressive analysis on the growth of Trikafta market during the forecast period 2021-2028 by taking into considerations several parameters including previous sales, competition from other drugs, increasing prevalence of cystic fibrosis, and unmet need of targeted drugs. The overall CFTR modulator market is highly competitive and consists of several pharmaceutical companies including Vertex Pharmaceuticals, Eloxx, Recode Therapeutics and Corbus Pharma which are investing huge amount in the development of novel CFTR modulators in the management of disease.
As per report findings, the global Trikafta market is estimated to surpass USD 5 Billion by 2028. The high growth rate during the forecast period can be justified by the high adoption rates in US and Europe. In addition, several ongoing clinical trials are also evaluating the role of drug in other mutations in different age groups, which are expected to gain approval in coming years.
Table of Contents
1. Elexacaftor/Ivacaftor/Tezacaftor (Trikafta/Kaftrio)
1.1 Overview
1.2 Patent & Assignees
2. Trikafta Commercial Information
2.1 Pricing & Dosage Analysis
2.2 Sales Analysis
3. Role in Cystic Fibrosis
4. Trikafta Mechanism of Action
5. Trikafta: Chemistry & Pharmacokinetic Properties
6. Trikafta Sales Forecast 2028
7. Trikafta Supplementary Information
7.1 Drug Interactions
7.1.1 Potential for other drugs to affect elexacaftor/tezacaftor/ivacaftor
7.1.2 Potential for elexacaftor/tezacaftor/ivacaftor to affect other drugs
7.2 Adverse Events
7.3 Use in Specific Population
8. Trikafta Reimbursement
9. Trikafta Clinical Trial Insights
9.1 By Phase
9.2 By Region
9.3 By Status
10. Global Market Analysis
10.1 Current Market Scenario
10.2 Future Market Opportunity
11. Ongoing Clinical Trials
12. Competitive Landscape
12.1 Abbvie
12.2 Eloxx Pharmaceuticals
12.3 GlaxoSmithKline
12.4 Mylan
12.5 Recode Therapeutics
12.6 Roche
12.7 Southern Research Institute
12.8 Spirovant Sciences
12.9 Translate Bio
12.10 Vertex Pharmaceuticals
List of Figures
Figure 1-1: US - Trikafta Orphan Drug Designation & FDA Approval Year
Figure 1-2: Europe - Trikafta Orphan Drug Designation & EMA Approval Year
Figure 1-3: US - Trikafta FDA Approval History by Mutation
Figure 1-4: US - Trikafta FDA Approval History in F508del Mutation by Age
Figure 1-5: Trikafta/Kaftrio - Initial Approval Year by Region
Figure 1-6: Europe - Kaftrio Approval & Patent Expiration Year
Figure 1-7: US - Trikafta Approval & Patent Expiration Year
Figure 1-8: US - Trikafta Patent Approval & Expiration Year
Figure 2-1: US - Cost of Supply of 84 Oral Tablet & Per Unit Cost of Trikafta Oral Tablet (US$), October'2021
Figure 2-2: Europe - Cost of Supply of 56 Oral Tablet & Per Unit Cost of Kaftrio Oral Tablet (Euro/US$), October'2021
Figure 2-3: UK - Cost of Supply of 56 Oral Tablet & Per Unit Cost of Kaftrio Oral Tablet (Euro/US$), October'2021
Figure 2-4: Trikafta/Kaftrio - Recommended Initial & Reduced Dose (mg/day)
Figure 2-5: Trikafta - Average Cost of Daily, Monthly & Annual Treatment of Cystic Fibrosis (US$), October'2021
Figure 2-6: Global - Trikafta/Kaftrio Annual Sales (US$ Million), 2019 & 2020
Figure 2-7: Global - Trikafta/Kaftrio Quarterly Sales (US$ Million), 2020
Figure 2-8: Global - Trikafta/Kaftrio Quarterly Sales (US$ Million), Q1 & Q2’2021
Figure 3-1: Frequency of CFTR Mutation by Class
Figure 4-1: CFTR Modulators - Specific Target for Different Approaches
Figure 4-2: Trikafta - Mechanism of Action at Molecular Level
Figure 5-1: Elexacaftor - Chemical Structure
Figure 5-2: Chemical Structure of Ivacaftor & Tezacaftor
Figure 6-1: Trikafta - Expected Sales Analysis (US$ Million), 2021 - 2028
Figure 9-1: Trikafta - Number of Clinical Trials by Phase, October’2021
Figure 9-2: Trikafta - Number of Clinical Trials by Phase (%), October’2021
Figure 9-3: Trikafta - Number of Clinical Trials by Region, October’2021
Figure 9-4: Trikafta - Number of Clinical Trials by Region (%), October’2021
Figure 9-5: Trikafta - Number of Clinical Trials by Status, October’2021
Figure 9-6: Trikafta - Number of Clinical Trials by Status (%), October’2021
Figure 10-1: Global - CFTR Modulator Market by Product (US$ Billion), 2020
Figure 10-2: Global - CFTR Modulator Market by Product (%), 2020
Figure 10-3: Global - CFTR Modulator Market by Product (US$ Billion), H1’2021
Figure 10-4: Global - CFTR Modulator Market by Product (%), H1’2021
Figure 10-5: Global - Estimated Cystic Fibrosis Incidence, 2021-2028
Figure 10-6: Global - Trikafta Market Opportunity in Cystic Fibrosis by 5% Adoption Rate (US$ Million), 2021 - 2028
Figure 10-7: Global - Trikafta Market Opportunity in Cystic Fibrosis by 10% Adoption Rate (US$ Million), 2021 - 2028
Figure 10-8: Global - Trikafta Market Opportunity in Cystic Fibrosis by 15% Adoption Rate (US$ Million), 2021 - 2028
Figure 10-9: Global - Trikafta Market Opportunity in Cystic Fibrosis by 20% Adoption Rate (US$ Million), 2021 - 2028
Figure 10-10: Global - Trikafta Market Opportunity in Cystic Fibrosis by 25% Adoption Rate (US$ Million), 2021 - 2028
Figure 10-11: Global - Trikafta Market Opportunity in Cystic Fibrosis by 30% Adoption Rate (US$ Million), 2021 - 2028
Figure 10-12: Global - Trikafta Market Opportunity in Cystic Fibrosis by 35% Adoption Rate (US$ Million), 2021 - 2028
Figure 10-13: Global - Trikafta Market Opportunity in Cystic Fibrosis by 40% Adoption Rate (US$ Million), 2021 - 2028
Figure 10-14: Global - Trikafta Market Opportunity in Cystic Fibrosis by 45% Adoption Rate (US$ Million), 2021 - 2028
Figure 10-15: Global - Trikafta Market Opportunity in Cystic Fibrosis by 50% Adoption Rate (US$ Million), 2021 - 2028
Figure 10-16: US - Estimated Cystic Fibrosis Incidence, 2021-2028
Figure 10-17: US - Trikafta Market Opportunity in Cystic Fibrosis by 5% Adoption Rate (US$ Million), 2021 - 2028
Figure 10-18: US - Trikafta Market Opportunity in Cystic Fibrosis by 10% Adoption Rate (US$ Million), 2021 - 2028
Figure 10-19: US - Trikafta Market Opportunity in Cystic Fibrosis by 15% Adoption Rate (US$ Million), 2021 - 2028
Figure 10-20: US - Trikafta Market Opportunity in Cystic Fibrosis by 20% Adoption Rate (US$ Million), 2021 - 2028
Figure 10-21: US - Trikafta Market Opportunity in Cystic Fibrosis by 25% Adoption Rate (US$ Million), 2021 - 2028
Figure 10-22: US - Trikafta Market Opportunity in Cystic Fibrosis by 30% Adoption Rate (US$ Million), 2021 - 2028
Figure 10-23: US - Trikafta Market Opportunity in Cystic Fibrosis by 35% Adoption Rate (US$ Million), 2021 - 2028
Figure 10-24: US - Trikafta Market Opportunity in Cystic Fibrosis by 40% Adoption Rate (US$ Million), 2021 - 2028
Figure 10-25: US - Trikafta Market Opportunity in Cystic Fibrosis by 45% Adoption Rate (US$ Million), 2021 - 2028
Figure 10-26: US - Trikafta Market Opportunity in Cystic Fibrosis by 50% Adoption Rate (US$ Million), 2021 - 2028
Figure 11-1: Trikafta - Phase-III Evaluating Long Term Efficacy in CF with F508del Mutation Initiation & Completion Year
Figure 11-2: Trikafta - Phase-III Evaluating Long Term Efficacy in CF with F/MF Mutation Initiation & Completion Year
Figure 11-3: Trikafta - Phase-III Evaluating Effect on Cough & Physical Activity Initiation & Completion Year
Figure 11-4: Trikafta - Phase-III Evaluating Glucose Tolerance in CF Initiation & Completion Year
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbvie
- Eloxx Pharmaceuticals
- GlaxoSmithKline
- Mylan
- Recode Therapeutics
- Roche
- Southern Research Institute
- Spirovant Sciences
- Translate Bio
- Vertex Pharmaceuticals
